Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

PRODIGE 25 (FFCD 11-01) - Phase II randomized trial evaluating aflibercept associated with LV5FU2 regimen as first line treatment of non-resectable metastatic colorectal cancers (FOLFA)

Date

08 Oct 2016

Session

Poster Display

Presenters

Jean Louis Legoux

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

J.L. Legoux1, K. Le Malicot2, R. Faroux3, V. Boige4, N. Barriere5, J. Egreteau6, Y. Rinaldi7, E. Maillard8, M. Baconnier9, C. Lecaille10, S. Herrmann-Gandara1, A. Vimal11, Y. Touchefeu12, J. Raimbourg13, T. Aparicio14

Author affiliations

  • 1 Hepato-gatroenterology And Digestive Oncology, C.H.R. Orleans - La Source, 45100 - Orleans/FR
  • 2 Biostatistics, Fédération Francophone de Cancérologie Digestive (FFCD), 21079 - Dijon/FR
  • 3 Service D'hge, CHD Vendee - Hopital Les Oudairies, 85925 - La Roche sur Yon/FR
  • 4 Digestive Oncology, Institut Gustave Roussy, Villejuif/FR
  • 5 Hepato-gatroenterology And Digestive Oncology, Hôpital Européen, Marseille/FR
  • 6 Medical Oncology, CH Sud Bretagne, Lorient/FR
  • 7 Service D'hge, Hôpital européen, Marseille/FR
  • 8 Hepato-gastroenterology, CH d'Annecy, Annecy/FR
  • 9 Hepato-gatroenterology And Digestive Oncology, CH d'Annecy, Annecy/FR
  • 10 Hepato-gatroenterology And Digestive Oncology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux/FR
  • 11 Medical Oncology, CHU Estaing, Clermont-Ferrand/FR
  • 12 Hepato-gastroenterology, CHU de Nantes, 44000 - Nantes/FR
  • 13 Medical Oncology, Institut de Cancérologie de l’Ouest, Nantes/FR
  • 14 Gastroenterology, Hôpital Avicenne, 93000 - Bobigny/FR
More

Resources

Abstract 3343

Background

Aflibercept has already been used in combination with FOLFIRI in the VELOUR trial (1). The aflibercept-LV5FU2 combination can be useful and well tolerated in patients (pts) with never resectable/non symptomatic metastatic colorectal cancer, for whom 5-FU monotherapy can be suggested to delay the toxicities of combined chemotherapies, then eligible for sequential treatment with first-line 5-FU monotherapy. Within this context, it is possible for aflibercept to provide a survival benefit. VELOUR trial did not indicate that toxicity would have a major effect on quality of life and increase the hope of prolonged progression-free survival in the arm with aflibercept. A previous pharmacogenetic analysis of the FFCD 2000-05 phase III trial (2) showed a prognostic and predictive effect of the thymidylate synthase (TS)-5'UTR polymorphism for response and PFS: the 5-FU monotherapy efficacy was increased in TS 5'3R/3R pts vs 2R2R-2R3R (2). Stratification in this criterion will confirm or not the prognostic or predictive value of these polymorphisms if linked to the 5-FU efficacy.

Trial design

The major eligibility criteria are: age ≥ 65, performance status WHO ≤ 2, central genotyping of TS in blood DNA. Treatment is administered every14 days with simplified LV5FU2 regimen, preceded or not by perfusion of 4 mg/kg aflibercept. The treatment will be stopped in case of progression (evaluation each 8 weeks) or inacceptable toxicity. The main judgement criterion is proportion of pts alive and without radiologic progression within 6 months. A proportion of more than 40% pts will be interesting and a rate of 60% is expected (α = 5%, Binomial-exact method and a power of 90%). Secondary criteria are: tolerance of the LV5FU2-aflibercept combination, time to final deterioration in quality of life, overall survival, prognostic value of TS-5'UTR polymorphism on PFS. Stratification factors are: centre, age:  75, TS-5'UTR polymorphism, metastatic site (1 vs >1). Status: 18 of planned 118 patients have been randomized. References: (1) Van Cutsem E et al: J Clin Oncol 30:3499-506, 2012 (2), Boige V et al: J Clin Oncol 28:2556-64, 2010

Clinical trial identification

EudraCT 2014-001837-10; 05 September 2014

Legal entity responsible for the study

FFCD

Funding

Sanofi

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings